Mental distress among adult patients with eosinophilic esophagitis

Willemijn E. de Rooij1 | Floor Bennebroek Evertsz2 | A. Lei1 | Albert J. Bredenoord1

1Department of Gastroenterology & Hepatology, Amsterdam University Medical Center, Amsterdam, the Netherlands
2Department of Medical Psychology, Amsterdam University Medical Center, Amsterdam, the Netherlands

Correspondence
Willemijn E. de Rooij, Department of Gastroenterology & Hepatology, Amsterdam University Medical Center, PO Box 22660, 1100 DD Amsterdam, the Netherlands.
Email: w.e.derooij@amsterdamumc.nl

ABSTRACT

Rationale: Data on the prevalence of mental distress among adult eosinophilic esophagitis (EoE) patients are scarce. Also, a significant gap remains in the understanding of which determinants are related to significant psychological symptoms and whether distressed patients require and receive mental care.

Methods: Adult EoE patients were invited to complete standardized measures on anxiety/depressive symptoms (HADS) and general psychopathology (SCL-90-R). All scores were compared to general population norms. Socio-demographic and clinical factors were assessed.

Results: In total, 147 adult EoE patients (61% males, age 43 (IQR 29–52) years were included (response rate 71%). No difference with general population values was found for total anxiety and depressive symptoms (7.8 ± 6.6 vs. 8.4 ± 6.3; p = 0.31). A total of 38/147(26%) patients reported high levels of anxiety and/or depressive symptoms (HADS-A ≥ 8: 35/147(24%) and HADS-D ≥ 8: 14/147(10%)), indicative of a possible psychiatric disorder. In a multivariate analysis, age between 18–35 years was independently associated with high levels of anxiety (HADS-A ≥ 8) (OR 3.0, 95% CI 1.3–6.9; p = 0.01). The SCL-90-R Global Severity Index (GSI) was significantly higher compared to the general population (p < 0.001). Significant signs of general mental distress (GSI ≥ 80th percentile) were observed in 51(36%) EoE patients, of which 29(57%) patients denied having any mental problems and only 8(16%) patients received mental care.

Conclusion: A considerable proportion of adult EoE patients suffers from mental distress, with a 3-fold risk of significant anxiety in those patients younger than 35 years. Therefore, population-based studies are required and a proactive approach in the screening for and treatment of these psychological symptoms in EoE practice seems essential.

KEYWORDS
anxiety, depression, Eosinophilic esophagitis, mental care, mental distress
1 | INTRODUCTION

EoE is a chronic immune-mediated disorder of the esophagus triggered by food allergens, with an increasing prevalence rates almost comparable to inflammatory bowel disease (IBD). EoE is characterized by mucosal eosinophilic infiltration and subsequent esophageal dysfunction, which manifests in symptoms of dysphagia for solid foods and food impaction. EoE affects all ages (3:1 male-to-female ratio), with a peak incidence between the ages of 20 and 40 years. At present, the management of EoE involves targeting the esophageal eosinophilic inflammation with drugs or elimination of food allergens. EoE is associated with a substantial disease burden that affects patients’ health-related quality-of-life (HRQOL), healthcare systems, and society in general. Multiple aspects such as disturbing symptoms of dysphagia and food impaction and the need for life-long treatment are associated with impaired HRQOL. A recent medical record review observed a prevalence of psychiatric health comorbidities in almost one-third of EoE patients, in which older age, female gender, and longer symptom duration were found to be associated with the presence of a mental health disorder. Current research has mainly focused on increased risk of developing anxiety and depressive symptoms, measured within the construct of disease specific HRQOL (EoE-QOL-A). This validated measure consists of 5 domains that evaluates important disease-related topics (e.g., issues related to having a chronic disease or swallowing anxiety) and has been widely used in the EoE research field. Still a significant gap remains in our understanding of the impact on mental health and its determinants in this chronic disease and if distressed EoE patients receive mental treatment. Notwithstanding, insufficient treatment of psychiatric comorbidities in patients with a chronic physical illness (e.g., IBD and rheumatoid arthritis) has been associated with more severe symptoms and disease flares, therapeutic non-adherence, and subsequent increased healthcare costs. However, provision of sufficient mental care in adult EoE patients first requires more insights into the presence of mental distress and its determinants (e.g., clinical and demographic factors). Therefore, we aimed to evaluate in this study: (a) the presence of mental distress among adult EoE patients, (b) the degree to which clinical and socio-demographic factors are related to significant levels of mental distress, and (c) if EoE patients with severe symptoms of general mental distress receive mental care.

2 | METHODS

2.1 | Study design and population

An observational cross-sectional study design was used to assess mental distress among adult EoE patients. Consecutive patients from our EoE cohort (i.e., patients who attended the outpatient clinic of the Amsterdam UMC Motility Center between 2011 and 2020) were invited to participate in this study between July 2019 and February 2020 (i.e., recruitment period). An informed consent letter including self-reported questionnaires was sent to the EoE cohort and distributed at the outpatient clinic during this recruitment period. Patients with a documented diagnosis of EoE according to the consensus guidelines (i.e., ≥15 eosinophils per high-power-field), aged 18 and over, with a sufficient command of written Dutch to complete a self-reported survey were considered eligible for inclusion. Once consented, all patients completed a paper or digital version of the questionnaires. All data were safely collected and stored by using the Electronic Data Capture Castor. A flowchart of patient inclusion and participation rate is presented in Figure 1.

2.2 | Data collection

2.2.1 | Socio-demographics and clinical outcomes

A self-designed (standard fixed choice) questionnaire was used to elicit details concerning socio-demographic and clinical information. socio-demographic variables, such as gender and education level (low: primary or secondary school and high: College or University) and specific information on the year of symptom onset and diagnosis of EoE, history of endoscopic interventions and previous dilations, EoE treatment (medical or dietary treatment) and concomitant atopic diseases, were included. In addition, patients were asked if they felt to have current mental health problems and whether they received mental care. Clinical symptoms of dysphagia and food impaction (i.e., clinical disease activity) were evaluated by means of the Straumann Dysphagia Instrument (SDI). Severe clinical disease activity was defined as current symptoms of daily dysphagia and food impaction.

2.3 | Study questionnaires and reference population

2.3.1 | Anxiety and depression

Anxiety and depressive symptoms were measured with the standardized and validated Hospital Anxiety and Depression Scale (HADS). This 14-item self-assessment scale was developed to screen for depression and anxiety symptoms (recall period of 7-days). The
HADS consists of 7 anxiety and 7 depression items, of which the total scores ranges from 0 (no complaints) to 21 (maximum complaints). A score of ≥8 on either subscales signifies a symptom severity indicative for a possible anxiety and/or depressive disorder. Anxiety and depression symptom scores of all EoE patients were compared to a subgroup of 199 patients, which was derived from 3492 respondents of the general Dutch population.

### 2.3.2 General mental distress

Symptoms of general mental distress were evaluated by means of the validated Symptom Checklist-90-Revised (SCL-90-R). This questionnaire consists of 90-items to assess for general self-reported psychological symptoms over the past 7 days. The SCL-90-R-items represent 8 domains, including agoraphobia, anxiety, depression, somatization, sensitivity, insufficiency of thinking and acting, hostility and sleep disturbance. Each item is rated on a 5-point scale of distress, ranging from 1 (none) to 5 (extreme). The total SCL-90-R score (Global Severity Index (GSI)) is calculated by substitution of all subdomain scores and ranges from 0 to 450, with higher scores indicative for mental distress. SCL-90-R-scores of our EoE sample were compared to a reference cohort of 2368 respondents (norm group II) of the Dutch general population. In addition, cut-off scores were used to identify patients with severe symptoms of general mental distress, indicated as GSI scores of “above normal” and “high” (corresponding to the 80th percentile of the norm group II), that are clinically relevant and may be indicative of a mental disorder.

### 2.4 Statistical analysis

Statistical analysis was performed by using IBM SPSS Statistics (version 25.0) (SPSS, Chicago, USA). Descriptive statistics was used to assess socio-demographic and clinical characteristics. Data are presented as mean (±Standard Deviation (SD)) or median (interquartile range (IQR)). To characterize our sample, levels of the validated Patient-Reported Outcome (PRO) measures (HADS/SCL-90-R) were compared to previously published general population norms. Independent sample t tests were used to compare mean scores of the HADS and SCL-90-R in EoE patients to the general population norms. Univariate logistic regression analyses were performed to identify (clinical relevant) factors associated with high levels of anxiety (HADS-A ≥ 8). Demographic variables with a p-value of <0.20 were subsequently entered into multivariate logistic regression analysis with backward selection. Associations between clinical disease activity (SDI scores) and HADS-A and HADS-D and all subscales of the SCL-90-R were assessed by Pearson’s or Spearman’s rank correlations coefficients, as appropriate. A p-value of <0.05 was considered to be statistical significant.

### 2.5 Ethical considerations

This cross-sectional study was conducted according to the principles of the Declaration of Helsinki and in accordance with the Medical Research Involving Human Subjects Act (WMO). An exemption to seek formal approval was provided by the Medical Ethics Committee.
of the Amsterdam UMC at 25-03-2019 (W19_103#19.136). All participants provided informed consent before taking part and were given an unique study-ID to ensure anonymity.

3 | RESULTS

3.1 | Patient characteristics

In total, 147 adult EoE patients were included (61% males, median age 43 (IQR 29–52) years), representing a response rate of 71%. Atopic constitution was observed in 119 (81%) patients. The median disease duration in our cohort was 3 (IQR 1–6) years, with 49 (33%) patients diagnosed within the prior year. Diagnostic delay, measured as time interval between first reported EoE symptoms and year of diagnosis, was 5 (IQR 2–14) years. In total, 21 (14%) patients had prior esophageal dilation and multiple endoscopic interventions with food bolus extraction were reported in 62 (42%) patients (Table 1).

3.2 | Anxiety and depressive symptoms

Evaluation of anxiety and/or depressive symptoms (HADS) showed no difference in the total HADS score in our EoE sample compared to the general population (7.8 ± 6.6 vs. 8.4 ± 6.3; p = 0.31) (Figure 2). Anxiety (HADS-A) and depression (HADS-D) symptom scores in EoE patients were also both similar compared to the general population (HADS-A: 4.8 ± 4.2 vs. 5.1 ± 3.6; p = 0.47 and HADS-D: 3 ± 3 vs. 3.4 ± 3.3; p = 0.1), respectively (Figure 2A). Additionally, no differences were observed for the HADS-total, HADS-A and HADS-D mean scores in female EoE patients compared to the general population (all; p > 0.05). Moreover, male EoE patients showed significantly lower HADS-total, HADS-A, and HADS-D scores compared to the general population (all; p < 0.05). In our EoE sample, significantly higher levels of the HADS-total score in females were observed compared to males (9.4 ± 7.9 vs. 6.8 ± 5.5; p = 0.02) (Figure 2B). Furthermore, significant higher levels of the HADS-A were detected in female EoE patients compared to males (6.1 ± 4.9 vs. 4.1 ± 3.6; p = 0.005), whereas HADS-D scores between male and female patients were similar (2.8 ± 2.5 vs. 3.4 ± 3.6; p = 0.226) (Figure 2B).

In our cohort, high levels of anxiety (HADS-A ≥ 8; indicative of an anxiety disorder) were observed in 35 (24%) patients, with no gender difference (male vs. female; p = 0.11). High levels of depression (HADS-D ≥ 8; indicative of an depressive disorder) were reported in 14 (10%) patients, whereas females were significantly more affected compared to males (6% vs. 16%; p = 0.048). Furthermore, 14 (10%) patients had high levels of both anxiety and depression (HADS-A ≥ 8 and HADS-D ≥ 8; indicative of both psychiatric disorders), of which the proportion of females was significantly higher (male 3% vs. female 14%; p = 0.023). Hence, a total of 38 (26%) patients (no difference between male vs. female; p = 0.123) scored high levels of anxiety and/or depressive symptoms; indicative of at least one of these psychiatric disorders.

3.3 | Associated factors with high levels of anxiety

Presence of high levels of anxiety (HADS-A ≥ 8; indicative of an anxiety disorder) was significantly more prevalent in young patients aged between 18–35 years (41%). Univariate analysis signifies a possible trend between high levels of anxiety and younger age (18–35 years), female gender, not being in domestic partnership, current symptoms of daily dysphagia and food impaction (severe clinical disease activity) and a short disease duration (≤2 years). However, after multivariate logistic regression analysis, age between 18–35 years was

---

**TABLE 1** Socio-demographic and clinical characteristics.

|                         | EoE, n (% or median (IQR) |
|-------------------------|---------------------------|
| **Socio-demographic characteristics** |                           |
| Age, years              | 43 (29–52)                |
| Gender, male            | 90 (61)                   |
| Level of education      |                           |
| Low                     | 49 (33)                   |
| High                    | 98 (67)                   |
| In domestic partnership |                           |
| No                      | 51 (35)                   |
| Yes                     | 96 (65)                   |
| **Clinical characteristics** |                           |
| Atopic diatheses        | 119 (81)                  |
| Current clinical disease activity |               |
| Dysphagia               | 97 (66)                   |
| Food impaction          | 41 (28)                   |
| Multiple endoscopic interventions with food bolus extraction | 62 (42) |
| Diagnostic delay<sup>a</sup>, years | 5 (2–14)                  |
| Disease duration, measured from year of diagnosis, years | 3 (1–6) |
| Age at symptom onset, years | 27 (19–38)               |
| Previous dilation       | 21 (14)                   |
| Current treatment       |                           |
| Topical steroids        | 35 (24)                   |
| Dietary restrictions    | 35 (24)                   |
| Topical steroids with additional dietary restrictions | 15 (10) |
| PPIs                    | 34 (23)                   |
| No treatment            | 28 (19)                   |

IQR, Interquartile Range; PPIs, Proton-Pump Inhibitors.
<sup>a</sup>Diagnostic delay is the time interval between the first symptoms and the diagnosis.
the only independent factor associated with high levels of anxiety (odds ratio (OR) 3.0, 95% confidence interval (CI) 1.3–6.9; \( p = 0.01 \) (Table 2).

### 3.4 | General mental distress

The general psychopathological profile of EoE patients was evaluated by means of self-reported symptoms of general mental distress (SCL-90-R), showing significantly higher levels of the GSI compared to the general population (135 ± 47.3 vs. 118.3 ± 32.3; \( p < 0.001 \)). In addition, levels of the symptom subscales; depression, somatization, insufficiency of thinking and acting, hostility and sleep disturbance and anxiety and sensitivity in EoE patients were all significantly higher compared to the general population (\( p < 0.001 \) and \( p < 0.05 \), respectively (Figure 3A). In addition, GSI levels of both male and female EoE patients were significantly higher compared to the general population (males: 131.7 ± 44.9 vs. 118.3 ± 32.3; \( p = 0.005 \) and females: 140.5 ± 51 vs. 118.3 ± 32.3; \( p = 0.002 \)), respectively. The subscales; anxiety, depression, somatization and insufficiency of thinking and acting.

### TABLE 2 | Determinant factors associated with high levels of anxiety.

| EoE patients | Univariate analysis | Multivariate analysis |
|--------------|---------------------|----------------------|
|              | High levels of anxiety (HADS-A ≥ 8) | OR (95% CI) | p-value | OR (95% CI) | p-value |
|              | N = 147 | N = 35 | n (%) | | | |
| Demographic variables | | | | | | |
| Female gender | 18 (32) | 1.982 | 0.919 to 4.274 | 0.081\(^\dagger\) | NS | NS |
| Age | | | | | | |
| 18–35 | 21 (41) | 3.123 | 1.375 to 7.092 | 0.007\(^\dagger\) | 2.999 | 1.307 to 6.881 | 0.01\(^\dagger\) |
| 36–55 | 13 (18) | Ref. | | | | |
| >55 | 1/25 (4) | | | | | |
| In domestic partnership | 19 (20) | 0.540 | 0.248 to 1.173 | 0.119\(^\dagger\) | NS | NS |
| Severe clinical disease activity | 6 (46) | 3.143 | 0.763 to 12.945 | 0.113\(^\dagger\) | NS | NS |
| Short disease duration (≤2 years) | 19 (31) | 1.906 | 0.886 to 4.100 | 0.099\(^\dagger\) | NS | NS |

Disease duration, measured from year of diagnosis.
OR, Odds Ratio; CI (95%), 95% Confidence interval; NS, Not significant; EoE, Eosinophilic esophagitis; P, percentile.

\(^\dagger\)p-value <0.2, indicating a possible trend.
\(^\dagger\)p-value of <0.05, indicating a significant outcome.
thinking and acting were significantly higher in both male and female EoE patients compared to the general population (all; \( p < 0.05 \)). In our EoE cohort, female patients showed significantly higher levels of the GSI compared to male patients \((127.3 \pm 42 \text{ vs. } 147.8 \pm 52; \ p = 0.017)\) and the subscales anxiety, depression, somatization and insufficiency of thinking and acting (male vs. female: \( p < 0.05 \)) (Figure 3B).

Severe symptoms of general mental distress, indicated as GSI scores of “above normal” and “high” (corresponding to the 80th percentile of the norm group II), were observed in 51 (36%) EoE patients, of which the proportion of females was significantly higher than males (46% vs. 29%; \( p = 0.048 \)). Evaluation of the symptom subscales for general mental distress (SCL-90-R) showed a significantly higher proportion of females with severe symptoms of depression (SCL-90-depression \( \geq 80^{th} \text{percentile} \)) and somatization (SCL-90-somatization \( \geq 80^{th} \text{percentile} \)) (male vs. female; \( p = 0.029 \) and \( p = 0.001 \), respectively). The percentages of patients in our EoE population exceeding the norm scores indicated as “above normal” and “high” (\( \geq 80^{th} \text{percentile} \)) in all dimensions of the SCL-90-R are presented in Figure 4.

In total, 22 (43%) patients with severe symptoms of general mental distress (GSI \( \geq 80^{th} \text{percentile} \)) reported to have current mental problems, of which only 8 (36%) patients received mental care and psychotropic medication (e.g., antidepressants or anxiolytics) was used in 7 (14%) patients. Fifteen (29%) patients with severe symptoms of general mental distress felt their mental problems were related to EoE. Of note, 29 (57%) patients with GSI scores exceeding the norm scores (\( \geq 80^{th} \text{percentile} \)) denied having any mental problems.

### 3.5 Associations between clinical disease activity and symptoms of mental distress

Ninety-seven (66%) patients reported current symptoms of dysphagia and 41 (28%) food impaction, of which 33 (81%) stated to have multiple episodes a week. Comparison of self-reported clinical disease severity and HADS-scores showed a significant positive correlation between the total SDI scores and both the HADS-A \( (r = 0.27; \ p = 0.001) \) and HADS-D \( (r = 0.19; \ p = 0.023) \) scores (Table S1). Additionally, SCL-90-R subscales agoraphobia, anxiety, depression, somatization, sensitivity, insufficiency of thinking and acting, hostility and sleep disturbance all showed a significant positive correlation with the total SDI score (all; \( p < 0.05 \)). (Table S1).

### 4 DISCUSSION

EoE is known to have impact on HRQOL of patients who suffer from the disease, although current literature is scarce on the understanding of mental health comorbidities in adult EoE patients. In this cross-sectional study, we observed a substantial presence of significant symptoms of mental distress among adult EoE patients. Although mean levels of anxiety and depression in our sample were not higher compared to the general population, relevant signs of anxiety (HADS-A \( \geq 8 \); indicative of an anxiety disorder) were seen in 24% patients. Moreover, high levels of depression (HADS-D \( \geq 8 \)) were noted in 14 (10%) patients. These observed rates are comparable to a study of Lucendo et al., in adult EoE patients, reporting significant signs of anxiety and depression in 31% and 10%, respectively. Furthermore, a remarkable finding in our study was the significant 3-fold risk for the presence of high levels of anxiety (HADS-A \( \geq 8 \)) in EoE patients between the ages of 18 and 35 years. The general onset of anxiety disorders usually occurs in childhood/adolescence, until they reach a peak in middle age, with tendency to decrease with older age. With regard to EoE, a pediatric study suggested anxiety symptoms to increase with age, including rates of 9.3% in children (<11 years) and 19% in adolescents (11–17 years). In our EoE sample, 41% of young adults (18–35 years) and 18% of the middle-aged (36–55 years) patients presented with significant signs of anxiety. Compared to prevalence rates of anxiety (HADS-A \( \geq 8 \)) in a general German population, which ranges from 14.4%–19.8% (<40 years) and 19.8%–25% (41–60 years), it is certain that young adults diagnosed with EoE are more at risk for the development of significant signs of anxiety.

Overall, females showed significantly higher levels of mental distress compared to males in our EoE sample. This finding is consistent with previous literature reports on female predominance of common mental disorders in the general population. For that reason, it seems notable that the proportion of males and females with significant signs of anxiety on both PRO measures (HADS-A \( \geq 8 \) and SCL-90- anxiety \( \geq 80^{th} \text{percentile} \)) were equally distributed in our EoE sample. Since men are more prone of stricture development with consecutive risk of increased symptom severity, one could argue that male EoE patients are more exposed to potential anxiety triggers such as impaction with need for upper endoscopy and food bolus dislodgement. This is supported by previous findings on the serious impact of dysphagia and food impaction on patients’ fear, and identification of increased symptom severity as predictor of both disease and choking anxiety. Although severe clinical disease activity was not independently associated with high levels of anxiety in our multivariate analysis, SDI scores significantly correlated with scores of the HADS-A and SCL-90-anxiety (Table S1).

Compared to the general population, a greater severity of mental distress in EoE patients was observed, with a substantial proportion of patients (36%) with severe symptom levels (GSI \( \geq 80^{th} \text{percentile} \)) in our sample. Nevertheless, these results should be interpreted with caution, since the SCL-90-R is not corrected for somatic disorders. In addition, the HADS anxiety and depression scores were not higher compared to the general population, whereas the SCL-90-R subscales anxiety and depression were significantly higher in EoE patients. Although a clear explanation is lacking, this inequality might be the result of the HADS being corrected for the presence of physical illness. Also, a more extensive screening as result of a higher number of items included in the SCL-90-R, in particular in the domain depression, might also be suggested as an explanation for this contrasting finding. Moreover, considering somatization (i.e., SCL-90-somatization) to be the most intense symptom in our sample, it could be argued that the presence of physical illness resulted in an
overestimation of the GSI score (Figure 3A and Figure 4). However, only the questions “pain in the chest or heart” (item 12) and “having a lump in the throat” (item 53) fits with EoE-related symptoms, suggesting these patients actually may experience somatic symptoms (e.g., difficulty to breath or dizziness) in response to their psychological distress. Moreover, the presence of EoE-related symptoms (SDI scores) significantly correlated with SCL-90-somatization levels ($r = 0.4; p < 0.001$), even if corrected for EoE-related symptoms by exclusion of SCL-90-items 12 and 53 (Table S1). Generally, there is a moderate association between symptoms and biological disease activity (esophageal inflammation) in non-dilated EoE patients.$^{26,27}$

We hypothesize that somatization of esophageal symptoms (e.g., dysphagia) in severe distressed EoE patients may help to explain additional variation in symptom severity, once variation in biological disease activity has already been taken into consideration. In IBD-patients, association between somatization and clinically active disease with absence of mucosal inflammation, was suggested to be secondary to somatoform-type behavior or a coexisting functional disease instead of being related to biological disease activity (i.e., mucosal inflammation or extraintestinal manifestations of IBD).$^{28}$ The concept of this so-called somatoform-type behavior might also play a role in EoE; the absence of
histological data in our cohort did not allow us to further address this hypothesis.

Despite their clinical and public health importance, the presence of psychological disorders is often underdiagnosed and undertreated, in particular when coexisting with physical illness. Significant signs of general mental distress (GSI ≥80 percentile) were observed in 51 (36%) EoE patients, of which 29 (57%) patients denied having any mental problems. Also, only 8 (16%) of these patients received mental care of which 7 (14%) patients reported current psychotropic medication use. Therefore, routine screening by gastroenterologists for symptoms of anxiety and depression in adult EoE patients through the mental health subscale of the Short Form (SF)-36 or Patient Health Questionnaire (PHQ)-4 could be suggested for clinical practice. As such, several drivers of disease-related anxiety, such as symptom severity and need for long-term food restrictions, have been indicated to be legitimate concerns for caregivers in pediatric EoE. Significant impacts on eating and food-specific anxieties emerging into a newly classified eating disorder; Avoidant/Restrictive Food Intake Disorder (ARFID) has already been observed in pediatric EoE and other digestive diseases. ARFID is characterized by extreme restrictive eating behaviors (i.e., disturbed feeding patterns, highly selective eating habits) and awareness on the presence of this specific mental disorder in adult EoE patients should also be increased.

Based on our results, it remains unclear whether distressed EoE patients’ felt they received the mental care they need. The World Health Organization (WHO) studied the consultation process for mental health reasons, in which the preference for self-management (i.e., managing one’s self) has been indicated as main barrier for not seeking mental treatment, even though need for mental care was perceived. In addition, especially young- and middle-aged patients are more likely to recognize need for treatment but experience more structural barriers to treatment seeking, such as negative attitude toward help seeking, financial problems, and time barriers. Therefore, also a proactive approach toward (unmet) needs for mental care could be suggested for clinical practice.

Several limitations of our study merit attention. First, including patients from a tertiary center is known for limiting the generalizability of outcomes. However, as we included patients from our EoE cohort and new patients visiting the outpatient clinic, our study sample reflects a various population containing different stages of disease activity. Additionally, considering patients with mental disorders often face stigma, psychotropic medication use may have been underreported in our study. Nevertheless, these limitations are encountered by several strengths of our study design. To the best of our knowledge, this is the first cross-sectional study with specific interest of evaluating the presence of mental distress among adult EoE patients and the extent to which clinical and socio-demographic factors are related. Considering the use of 2 validated PRO measures (HADS/SCL-90-R), new insights are provided on the psychopathological profile of adult EoE patients. Another strength of our study lies in the large sample size of our cohort including EoE patients from various geographical areas in the Netherlands.

In conclusion, we observed a substantial presence of mental distress among adult EoE patients, with a compelling 3-fold risk of significant signs of anxiety during young adulthood (18–35 years). These findings are highlighting the need for future population-based studies on the prevalence of mental distress. Since EoE mostly affects young adults, screening for and treatment of mental health disorders should therefore become an integral part of the medical care of EoE patients.

ORCID
Willemijn E. de Rooij https://orcid.org/0000-0002-1691-6270

REFERENCES
1. Dellon ES, Hirano I. Epidemiology and natural history of eosinophilic esophagitis. Gastroenterology. 2018;154:319-332.e3.
2. Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142:46-54.e42.
3. Dellon ES, Liacouras CA, Molina-Infante J, et al. Updated International Consensus Diagnostic Criteria for Eosinophilic Esophagitis: Proceedings of the AGREE Conference. Gastroenterology. 2018;155(4):1022-1033.e10.
4. Mukkada V, Falk GW, Eichinger CS, et al. Health-related quality of life and costs associated with eosinophilic esophagitis: a systematic review. Clin Gastroenterol Hepatol. 2018;16:495-503.e8.
5. Lucendo AJ, Arias-González L, Molina-Infante J, Arias Á. Determinant factors of quality of life in adult patients with eosinophilic esophagitis. United Eur Gastroenterol J. 2018;6:38-45.
6. van Rijn BD, Smout AJPM, Bredenoord AJ. Disease duration determines health-related quality of life in adult eosinophilic esophagitis patients. Neurogastroenterol Motil Off J Eur Gastrointest Motil Soc. 2014;26:772-778.
7. Safroneeva E, Coslovsky M, Kuehni CE, et al. Eosinophilic oesophagitis: relationship of quality of life with clinical, endoscopic and histological activity. Aliment Pharmacol Ther. 2015;42:1000-1010.
8. Reed CC, Corder SR, Kim E, et al. Psychiatric comorbidities and psychiatric medication use are highly prevalent in patients with eosinophilic esophagitis and associate with clinical presentation. Am J Gastroenterol. 2020;115:853-858.
9. Lucendo AJ, Sánchez-Cazalla M, Molina-Infante J, et al. Transcultural adaptation and validation of the "Adult Eosinophilic Esophagitis Quality of Life Questionnaire" into Spanish. Rev Esp Enfermedades Dig. 2014;106:386-394.
10. Stern E, Taft T, Zalewski A, Gonsalves N, Hirano I. Prospective assessment of disease-specific quality of life in adults with eosinophilic esophagitis. Dis. Esophagus. 2018;31:1-7.
11. Taft TH, Kern E, Kwiatek MA, Hirano I, Gonsalves N, Kheefer L. The adult eosinophilic oesophagitis quality of life questionnaire: a new measure of health-related quality of life. Aliment Pharmacol Ther. 2011;34:790-798.
12. Creed F, Morgan R, Fiddler M, et al. Depression and anxiety impair health-related quality of life and are associated with increased costs in general medical inpatients. Psychosomatics. 2002;43:302-309.
13. Yilmaz V, Umay E, Gundogdu I, Ozgur Karaahmet Z, Ozturk AE. Rheumatoid Arthritis: are psychological factors effective in disease flare? Eur J Rheumatol. 2017;4:127-132.
14. DiMatteo MR, Lepper HS, Crogan TW. Depression is a risk factor for noncompliance with medical treatment meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med. 2000;160:2101-2107.
15. Straumann A, Conus S, Degen L, et al. Budesonide is effective in adolescent and adult patients with active eosinophilic esophagitis. Gastroenterology. 2010;139(5):1526-1537.e1.
16. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. *Acta Psychiatry Scand.* 1983;67:361-370.
17. Spinhow PH, Ormel J, Sloekers PP, Kempen GI, Speckens AE, Van Hemert AM. A validation study of the Hospital Anxiety and Depression Scale (HADS) in different groups of Dutch subjects. *Psychol Med.* 1997;27:363-370. Copyr. # 1997 Cambridge Univ. Press. https://doi.org/10.1016/S0163-8343(03)00043-4
18. Arrindell WA, Ettema JHM. SCL-90. Handleiding bij multidimensionale psychopathologie-indicator. Swets & Zeitlinger, 2003.
19. Ettema JHM, Arrindell WA. SCL-90. Handleiding bij een multidimensionele psychopathologie-indicator. Lisse: Swets & Zeitlinger; 2003.
20. Krasucki C, Howard R, Mann A. The relationship between anxiety disorders and age. *Int J Geriatr Psychiatry.* 1998;13:79-99.
21. Chehade M, Jones SM, Pesek RD, et al. Phenotypic Characterization of Eosinophilic Esophagitis in a Large Multicenter Patient Population from the Consortium for Food Allergy Research. *J Allergy Clin Immunol Pract.* 2018;6:1534-1544.e5.
22. Hinz A, Brähler E. Normative values for the hospital anxiety and depression scale (hads) in the general german population. *J Psychosom Res.* 2011;71:74-78.
23. Salk RH, Hyde JS, Abramson LY. Gender differences in depression in representative national samples: meta-analyses of diagnoses and symptoms. *Psychol Bull.* 2017;143:783-822.
24. McLean CP, Asnaani A, Litz BT, Hofmann SG. Gender differences in anxiety disorders: prevalence, course of illness, comorbidity and burden of illness. *J Psychiatr Res.* 2011;45:1027-1035.
25. Warners MJ, Oude Nijhuis RAB, De Wijkerslooth LRH, Smout AJPM, Bredenoord AJ. The natural course of eosinophilic esophagitis and long-term consequences of undiagnosed disease in a large cohort. *Am J Gastroenterol.* 2018;113:836-844.
26. Chang JW, Yeow RY, Waljee AK, Rubenstein JH. Systematic review and meta-regressions: management of eosinophilic esophagitis requires histologic assessment. *Dis Esophagus.* 2018;31(8). https://doi.org/10.1093/dote/doy049
27. Safroneeva E, Cotton CC, Schoepfer AM, Zwahlen M, Woosley JT, Dellon ES. Dilation Modifies Association Between Symptoms and Esophageal Eosinophilia in Adult Patients With Eosinophilic Esophagitis. *Am J Gastroenterol.* 2020;115:2098-2102.
28. Gracie DJ, Williams CJ, Sood R, et al. Poor Correlation Between Clinical Disease Activity and Mucosal Inflammation, and the Role of Psychological Comorbidity, in Inflammatory Bowel Disease. *Am J Gastroenterol.* 2016;111:541-551.
29. Demyttenaere K, Bruffaerts R, Posada-Villa J, et al. Prevalence, severity, and unmet need for treatment of mental disorders in the World Health Organization World Mental Health Surveys. *JAMA.* 2004;291:2581-2590.
30. Kroenke K, Spitzer RL, Williams JBW, Löwe B. An ultra-brief screening scale for anxiety and depression: the PHQ-4. *Psychosomatics.* 2009;50:613-621.
31. Means-Christensen AJ, Arnau RC, Tonidandel AM, Bramson R, Meagher MW. An efficient method of identifying major depression and panic disorder in primary care. *J Behav Med.* 2005;28:565-572.
32. Bennebroek Evertsz F, Sprangers MA, de Vries LM, et al. I am a total failure: associations between beliefs and anxiety and depression in patients with inflammatory bowel disease with poor mental quality of life. *Behav Cogn Psychother.* 2020;48:91-102.
33. Robson J, Laborda T, Fitzgerald S, et al. Avoidant/Restrictive Food Intake Disorder in Diet-treated Children with Eosinophilic Esophagitis. *J Pediatr Gastroenterol Nutr.* 2019;69:57-60.
34. Zimmerman J, Fisher M. Avoidant/Restrictive Food Intake Disorder (ARFID). *Curr Prob Pediatr Adolesc Health Care.* 2017;47:95-103.
35. Andrade LH, Alonso J, Mneimneh Z, et al. Barriers to mental health treatment: results from the WHO World Mental Health surveys. *Psychol Med.* 2014;44:1303-1317.
36. Park-Lee E, Lipari RN, Hedden SL, Kroutil LA, Porter JD. Receipt of Services for Substance Use and Mental Health Issues Among Adults: Results from the 2016 National Survey on Drug Use and Health. 2017 Sep. In: CBHSQ Data Review. Rockville (MD): Substance Abuse and Mental Health Services Administration (US); 2012.
37. World Health Organization - Regional Office for Europe. The European Mental Health Action Plan 2013–2020. World Heal. Organ. 19 (2015). https://www.euro.who.int/en/publications abstracts/european-mental-health-action-plan-20132020-the
38. Jagdeo A, Cox BJ, Stein MB, Sareen J. Negative attitudes toward help seeking for mental illness in 2 population-based surveys from the United States and Canada. *Can J Psychiatry.* 2009;54(11):757-766. https://doi.org/10.1177/070674370905401106

**SUPPORTING INFORMATION**

Additional supporting information may be found online in the Supporting Information section.

**How to cite this article:** Rooij WE, Bennebroek Evertsz F, Lei A, Bredenoord AJ. Mental distress among adult patients with eosinophilic esophagitis. *Neuropsychroenterology & Motility.* 2021;33:e14069. [https://doi.org/10.1111/nmo.14069](https://doi.org/10.1111/nmo.14069)